N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors
This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.
1. An N-acylhydrazone derivative represented by Formula I
a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein
R 1 represents hydrogen; and
A represents
a cycloalkyl group; or
a thienyl group;
or A together with R 2 , together with the carbon atom to which they are attached, form a naphthalene or hydrogenated naphthalene ring, which naphthalene and hydrogenated naphthalene are optionally substituted one or more times with substituents selected from alkyl and oxo; and
R 2 represents hydrogen or alkyl; or
R 2 together with A, and together with the carbon atom to which they are attached, form a naphthalene or hydrogenated naphthalene ring, which naphthalene and hydrogenated naphthalene are optionally substituted one or more times with substituents selected from alkyl and oxo.
2. The N-acylhydrazone derivative according to claim 1 , a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein R 2 together with A, and together with the carbon atom to which they are attached, form a naphthalene or hydrogenated naphthalene ring, which naphthalene and hydrogenated naphthalene are optionally substituted one or more times with substituents selected from alkyl, and in particular methyl, and oxo.
3. The N-acylhydrazone derivative according to claim 1 , which is
3-(1H-Indol-3-yl)-propionic acid [1-thiophen-3-yl-meth-(E)-ylidene]-hydrazide;
3-(1H-Indol-3-yl)-propionic acid [1-cyclohexyl-meth-(E)-ylidene]-hydrazide;
3-(1H-Indol-3-yl)-propionic acid [3,4-dihydro-2H-naphthalen-(1E)-ylidene]-hydrazide; or
3-(1H-Indol-3-yl)-propionic acid [3-methyl-4-oxo-4H-naphthalen-(1Z)-ylidene]-hydrazide;
a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising:
a therapeutically effective amount of an N-acylhydrazone derivative of claim 1 , a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof;
together with at least one pharmaceutically-acceptable carrier or diluent.
5. A composition comprising:
0.1 to 500 mg of an N-acyl derivative of claim 1 , a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically-acceptable acid addition salt thereof; and
at least one pharmaceutically-acceptable carrier or diluent.
6. A composition comprising:
to 100 mg of an N-acyl derivative of claim 1 , a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically-acceptable acid addition salt thereof; and
at least one pharmaceutically-acceptable carrier or diluent.
7. A composition comprising:
to 10 mg of an N-acyl derivative of claim 1 , a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically-acceptable acid addition salt thereof; and at least one pharmaceutically-acceptable carrier or diluent.
8. The N-acylhydrazone derivative according to claim 1 , which is 3-(1H-Indol-3-yl)-propionic acid [1-thiophen-3-yl-meth-(E)-ylidene]-hydrazide or a pharmaceutically acceptable salt thereof.
9. The N-acylhydrazone derivative according to claim 1 , which is 3-(1H-Indol-3-yl)-propionic acid [1-cyclohexyl-meth-(E)-ylidene]-hydrazide or a pharmaceutically acceptable salt thereof.
10. The N-acylhydrazone derivative according to claim 1 , which is 3-(1H-Indol-3-yl)-propionic acid [3,4-dihydro-2H-naphthalen-(1E)-ylidene]-hydrazide or a pharmaceutically acceptable salt thereof.
11. The N-acylhydrazone derivative according to claim 1 , which is 3-(1H-Indol-3-yl)-propionic acid [3-methyl-4-oxo-4H-naphthalen-(1Z)-ylidene]-hydrazide or a pharmaceutically acceptable salt thereof.